Roivant Sciences Ltd.
ROIV
株式のランク
#978
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
株価
$33.73
最終同期: 2026-07-31
時価総額
$24.37B
変化（1日）
-2.28%
変化（1年）
95.44%
国
GB
取引 Roivant Sciences Ltd. (ROIV)
カテゴリー
Healthcare
Roivant Sciences Ltd.（ROIV）のEPS
June 2026 時点のEPS TTM: $-0.38
Roivant Sciences Ltd.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-0.38です。2024年末には、EPSは$5.55で、2023年のEPS$-1.42と増加でした。
Roivant Sciences Ltd.のEPS履歴（2020から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-0.38 | 58.33% |
| 2025 | $-0.24 | -104.32% |
| 2024 | $5.55 | -490.85% |
| 2023 | $-1.42 | 12.70% |
| 2022 | $-1.26 | 6.78% |
| 2021 | $-1.18 | -167.43% |
| 2020 | $1.75 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -4,657.89% |
US
|
|
| $-7.98 | 2,000.00% |
US
|
|
| $-5.29 | 1,292.11% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -7,400.00% |
NL
|
